Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics Inc. is advancing its clinical pipeline with cadisegliatin, an oral liver-selective glucokinase activator currently in Phase 3 trials for type 1 diabetes, enhancing its market potential. The company's updated projections reflect improved market penetration rates, increasing the risk-adjusted discounted cash flow (DCF) valuation and reflecting greater long-term conviction in the therapeutic's prospects. With continued positive developments in ongoing studies and a strategic positioning in a market with limited competition for oral therapies, vTv Therapeutics's outlook appears promising.

Bears say

vTv Therapeutics's stock outlook appears negative primarily due to the inherent clinical risks associated with its lead product, cadisegliatin, which is still in late-stage development and may face challenges such as slower patient enrollment and unanticipated safety or efficacy results that could fail to meet expectations. The historical issues with first-generation glucokinase activators, which resulted in complications such as excessive hypoglycemia and worsening lipid profiles, highlight significant concerns regarding the efficacy and safety of vTv's therapeutic approach. Furthermore, the troubling statistic that nearly 80% of adults with type 1 diabetes do not achieve the American Diabetes Association's A1C goal of <7% underscores the potential limitations in addressing chronic disease management effectively, complicating vTv's prospects for successful market penetration.

vTv Therapeutics (VTVT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $55.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $55.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.